Navigation Links
Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board

The Madras High Court in the southern Indian state of Tamil Nadu has decided to transfer the Novartis AG’s appeal against the rejection of its patent// plea for the anti-cancer drug Glivec to the Intellectual Property Appellate Board.

The decision could be considered a temporary setback to the pharma multinational.

For it cannot hope for any early decision on the patent plea. The Appellate Board’s ruling too can be challenged it in the courts.

To add to Novartis’ miseries the technical member of the new appellate court will be none other than Chandrasekaran, former Controller General of the Indian Patent Office, who had rejected its application for Glivec patent. A spokesperson of the Novartis has already expressed concern over Chandrasekaran’s appointment.

The Madras High Court has already reserved its orders on the main petition by the Novartis challenging the constitutional validity of the Section 3(d) of the Patents (Amendment) Act.

Novartis contends the amendment contravenes the trade-related intellectual property rights (TRIPS) and also Article 14 of the Indian Constitution, which ensures equality before the law.

The section 3(d) of India’s 2005 Patent Amendment Act interprets the trade-related intellectual property rights (TRIPS) treaty. It prohibits patents for a new form of a known substance unless that new form has considerably better efficacy.

Novartis’s Glivec was a new form of an older molecule that it first patented in 1993. The enhancement in efficacy over the old form was not large enough to warrant a patent, the Patent Controller of India held in January last year.

The company then approached Madras High Court as the Controller’s office is situated in Chennai. It wanted rejection of patent application set aside. That appeal goes before the appellate board set up by the government of India for the purpose.

But orders on the Novartis’ challenge of the amendment to the patents law have been reserved. They could be delivered in a month or so from now.

And if a company like the Novartis gets its step in the door, asserting its right to patent even minor modifications of existing formulations, drug prices could go through the roof.

No firm then can manufacture generic drugs, which are less expensive. As patents near expiration, manufacturers apply for permission to sell generic versions. Because those manufacturers don’t have the same development costs, they can sell their product at substantial discounts. Also, once generic drugs are approved, there is greater competition, which keeps the price down. Today, almost half of all prescriptions are filled with generic drugs. Generic variations are introduced in colors, flavors, and certain other inactive ingredients.

To cite a specific example of the benefits of generic versions, the cost of patented HIV/AIDS drugs is huge whereas the generic is very cheap and affordable. Hence activists the world have raised serious concerns over the Novartis case in the Madras High Court.

The company has patented Glivec in nearly 40 countries worldwide and says it wants to ensure that it will get adequate patent protection for any drugs it plans to offer in India in the future. 'For a research-based organisation like Novartis, patents are non-negotiable, said a spokesperson for Novartis. 'This is the core of our business model and we cannot work in markets where there aren’t effective patent systems. It’s not about stopping generics. We are a major generics manufacturer.'

The stakes are high, say activists. 'Should Novartis succeed in its challenge, it will mark the first time that the demands of a private multinational corporation have overridden a sovereign country’s right to protect the health of its people,' said Chan Park of the Lawyers’ Collective HIV/AIDS Unit in New Delhi, which has campaigned against the case. < br>
Source-Medinia
GPL/B
'"/>




Related medicine news :

1. Indian Prime Minister has successful Knee Replacement Surgery
2. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
3. Indian Doctor granted US patent on organ regeneration
4. Heart attack kills one in every 10 Indians
5. Indian Cherry: Richest Source of Vitiamin C
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. An Indian Bride with signs of SARS
8. Are Indians aware of SARS ?
9. Indians Stay Away from Coke, Pepsi After Toxin Scare
10. Indian pharma industry upbeat on WTO drug deal
11. Indian Treatment for Iraqi Babies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... program today with a new Indiegogo campaign . Individuals are now able to ... the Los Angeles area, either as a participating patient or through an Indiegogo donation. ...
(Date:2/23/2017)... ... 2017 , ... Carlos Gutierrez has lived his spiritual life hardly ... which is the purpose of everyone in this universe. As Gutierrez sees the need ... Press) attempts to guide readers to expand one’s spiritual life. , “Our Spiritual Truths” ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy ... The technology is so cutting edge, in fact, the U.S. Food and Drug ... procedures. However, successful patient outcomes in certain clinical stem cell procedures have shown ...
(Date:2/22/2017)... ... February 22, 2017 , ... South Bend’s Lunkerville, the award-winning ... again feature Heroes On The Water (HOW), a non-profit organization dedicated to helping military ... has series host ‘Mike D’ traveling to Lake Denmark, New Jersey, to fish with ...
(Date:2/22/2017)... ... February 22, 2017 , ... A ... smaller and sometimes harder to reach ones, according to the results of a ... Stroke Conference in Houston by Ricardo A. Hanel, MD, PhD, neurovascular surgeon with ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Wash. and VANCOUVER, British Columbia ... (NASDAQ: OGXI ) today announced its year ... In January 2017, OncoGenex, and Achieve Life ... that they have entered into a definitive merger agreement ... transaction. Upon completion of the proposed merger, Achieve,s stockholders ...
(Date:2/23/2017)... , Feb. 22, 2017 Orthopedic and ... demand, as aging demographic patterns lead to an ... for sports- and exercise-related injuries, chronic back problems, ... lead sales gains. The future of medical implants ... the following questions and more: - What ...
(Date:2/23/2017)... , Feb. 22, 2017 Summary ... lymphoma partnering deals and agreements entered into by ... full report: http://www.reportlinker.com/p03605669-summary/view-report.html Description The ... 2010 report provides understanding and access to partnering ... leading healthcare companies. - Trends in ...
Breaking Medicine Technology: